Zerit (stavudine)
- Region
- 🇪🇺 EU
- Active substance
- stavudine
- Company
- Bristol-Myers Squibb Pharma EEIG
- Status
- Withdrawn
- Therapeutic area
- HIV Infections
- EU approval
- Wed 08 May 1996
- Application
- EMEA/H/C/000110
- ATC
- J05AF04
- Official record
- www.ema.europa.eu
Indication
Hard capsules Zerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (over the age of three months) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible. Powder for oral solution Zerit is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected adult patients and paediatric patients (from birth) only when other antiretrovirals can not be used. The duration of therapy with Zerit should be limited to the shortest time possible.
Regulatory milestones
No milestones recorded in the last year.
Follow Zerit
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.